About You

Patients should then be tested after weeks. Testosterone undecanoate is typically re-administered at a time point 4 weeks after initial dosing and then every 10 weeks thereafter. The Panel recommends testing no sooner than four weeks after commencement. Given the mechanisms of action of anastrozole, clomiphene citrate, and hCG, patients using these medications should wait a longer period before follow-up blood work is performed. In addition to issues relating to the reliability of compounded products themselves, appropriate clinical studies on pharmacokinetics are lacking. Overall, only 50% of Batch One and 30% of Batch Two samples achieved a potency within 20% of the prescribed dose.
Patients should be informed that there is no definitive evidence linking testosterone therapy to a higher incidence of venothrombolic events. Patients should be informed that the evidence is inconclusive whether testosterone therapy improves cognitive function, measures of diabetes, energy, fatigue, lipid profiles, and quality of life measures. Serum estradiol should be measured in testosterone deficient patients who present with breast symptoms or gynecomastia prior to the commencement of testosterone therapy. The use of validated questionnaires is not currently recommended to either define which patients are candidates for testosterone therapy or to monitor symptom response in patients on testosterone therapy. Clinicians should use a total testosterone level below 300 ng/dL as a reasonable cut-off in support of the diagnosis of low testosterone. Given the clinical and commercial testosterone landscape, the American Urological Association (AUA) identified a need to produce an evidence-based document that informs clinicians on the proper assessment and management of patients with testosterone deficiency. Sleep deprivation can significantly reduce testosterone levels.
The testosterone therapeutic space is relatively unique. Expert Opinion refers to a statement, achieved by consensus of the Panel, that is based on members\' clinical training, experience, knowledge, and judgment for which there is no evidence. A Clinical Principle is a statement about a component of clinical care that is widely agreed upon by urologists or other clinicians for which there may or may not be evidence in the medical literature. Where gaps in the evidence existed, the Panel provides guidance in the form of Clinical Principles or Expert Opinion with consensus achieved using a modified Delphi technique if differences of opinion emerged. Conditional Recommendations also can be supported by any evidence strength. Body of evidence strength Grade C is only rarely used in support of a Strong Recommendation. All three statement types may be supported by any body of evidence strength grade.
Selection of the administration route of testosterone is influenced by patient preference, product availability, and the cost of the formulation. In the mid-1950s, long-acting testosterone esters (enanthate and cypionate) were introduced, and have since been the preferred testosterone formulation thanks to their affordability, longer half-life compared to propionate, and predictable pharmacokinetics (9). We have come a long way since the days of Brown-Séquard, who self-administered an extract of animal testes by subcutaneous (SC) injection in 1889 (Fig. 1) (3). Systematic review of available literature on SC testosterone administration including clinical trials, case series, and case reports. Recently, subcutaneous (SC) administration of testosterone esters has gained popularity, as self-administration is easier with this route.
Testosterone enanthate administered weekly by an autoinjector may provide a viable option for some men with hypogonadism.76 Testosterone undecanoate in castor oil is also available as a 250 mg/mL deep intramuscular injection (Aveed®) in the United States. The short acting testosterone propionate was available in 1939 and the medium longer acting testosterone enanthate in 1954. Because only about 10 percent of testosterone is absorbed into the subdermal tissues, the rest remains on the skin until it is washed off. A 2% testosterone lotion (Axiron, not hydroalcoholic) was developed to be applied to the axilla.
As an aside, Sustanon is an interesting blend of esters, it was designed to achieve stable levels. SHBG which binds to testosterone is often the determining factor in deciding injection frequency. Another protein to be taken into consideration is albumin, formed in the liver, which has a weaker affinity for testosterone so still reduces the free testosterone level. The current UK reference range of nmol/l is very non-specific, doctors do not take age into consideration despite knowing there is an age-related decline in testosterone. The aim of dosing is to build up the plasma concentration of testosterone so that it achieves an optimal level according to your genetics, physiology and utilisation.
In this study, testosterone enanthate was administered via IM (single 200-mg dose) or SC injection (50 or 100 mg/week for 6 weeks) to 39 hypogonadal men (serum total testosterone 25). IM injections of long-acting testosterone esters (cypionate or enanthate) are cost-effective and result in physiological and predictable on-treatment serum testosterone levels, particularly when smaller doses are administered weekly (18). TESTIM® 1% gel is available as a unit‐dose tube containing the recommended starting dose of 50 mg of T in 5 g of gel.69 Serum T level measurements should be performed 14 days after starting treatment, and daily doses may be increased to 100 mg (2 tubes) if serum T levels are below the normal range (10.4–34.7 nmol/L, or 300–1000 ng/dl). In a long‐term follow‐up to this study, DHT levels were generally within the normal reference range (0.4–3.3 nmol/L, or 11.2–95.5 ng/dl), and 77.9% of patients continuing with AndroGel® 1.62% treatment maintained Cavg within the normal range on day 364 (mean total T concentration, 15.8 nmol/L, or 455 ng/dl), confirming the results observed in the double‐blind phase of the study.66 There were a few outliers who had residual pituitary function, these patients were noted to have a primary hypogonadism, their total testosterone levels were still only just above baseline.
The dose adjustment should aim at testosterone ranges usually within the mid adult male reference range. Upon close skin contact, there may be skin-to-skin transfer of testosterone to another person, which could increase serum testosterone concentrations in women and children.52-54 Before coming into close skin contact with another person, the area of testosterone gel application should be washed with soap and water or covered by clothing. 44 A 1.62% AndroGel® is supplied as a pump where one actuation delivers 20.25 mg of testosterone.47,48 The pharmacokinetic profile and safety profile is similar to the 1% gel but the recommended starting dose is 40.5 mg or two actuations which is less than 50 mg recommended for the 1 % gel. Testosterone gel relieves the symptoms of low testosterone, restores sexual function and mood, increases lean mass and bone mineral density, and decreases fat mass in testosterone deficient men.44-46 In contrast to the testosterone patches, testosterone gel causes minimal skin irritation (5.6% of patients) but has the anticipated adverse effects of androgens including acne, oiliness of skin, urinary symptoms. After application of the hydro-alcoholic gel, about 10 percent of the testosterone is absorbed in the subdermal area forming a reservoir where the testosterone is released slowly into the blood stream providing a relatively steady serum testosterone concentration. Table 1 shows the available testosterone replacement options in the United States (US) which includes topical patch and gels; nasal gel and buccal tablets; oral pills and capsules; injections and implants. Each patient needs to be aware of the possible risks to himself and balance that against the proven beneficial effects of testosterone treatment.

Profile Info